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To understand the mechanisms that mediate germline genetic leukemia predisposition, we
studied the inherited ribosomopathy Shwachman-Diamond syndrome (SDS), a bone marrow
failure disorder with high risk of myeloid malignancies at an early age. To define the
mechanistic basis of clonal hematopoiesis in SDS, we investigate somatic mutations acquired
by patients with SDS followed longitudinally. Here we report that multiple independent
somatic hematopoietic clones arise early in life, most commonly harboring heterozygous
mutations in EIF6 or TP53. We show that germline SBDS deficiency establishes a fitness
constraint that drives selection of somatic clones via two distinct mechanisms with different
clinical consequences. EIF6 inactivation mediates a compensatory pathway with limited
leukemic potential by ameliorating the underlying SDS ribosome defect and enhancing clone
fitness. TP53 mutations define a maladaptive pathway with enhanced leukemic potential by
inactivating tumor suppressor checkpoints without correcting the ribosome defect. Sub-
sequent development of leukemia was associated with acquisition of biallelic TP53 altera-
tions. These results mechanistically link leukemia predisposition to germline genetic
constraints on cellular fitness, and provide a rational framework for clinical surveillance
strategies.
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enetic predisposition to myeloid malignancy comprises a
separate disease entity in the WHO classification1. Diag-
nosis of leukemia predisposition provides potential
opportunities for early intervention, but data to guide precision
medicine approaches to clinical surveillance are lacking.
Shwachman-Diamond syndrome (SDS) is a genetic disorder
associated with a high risk of developing myeloid neoplasms
(MN) early in life2–4. SDS is predominantly caused by biallelic
germline mutations in the SBDS gene5. The SBDS protein pro-
motes formation of the mature, translationally active 80S ribo-
some by cooperating with the GTPase EFL1 to catalyze the
removal of EIF6 from the 60S ribosomal subunit. In the absence
of SBDS, EIF6 remains bound to the 60S subunit and sterically
inhibits its joining to the 40S subunit6). In SDS cells, SBDS
deficiency impairs eviction of EIF6 from the nascent 60S subunit,
resulting in decreased ribosomal subunit joining and reduced
translation efficiency6. Activation of cellular senescence pathways
by ribosome stress incurs a global fitness defect in hematopoietic
stem and progenitor cells which manifests clinically as bone
marrow failure7–9.
Survival of patients with SDS who develop myelodysplastic
syndrome (MDS) or acute myeloid leukemia (AML) is poor10.
Therefore, a central goal in clinical care of SDS patients is to
identify incipient leukemic transformation and initiate pre-
emptive treatment with allogeneic stem cell transplantation.
Current surveillance strategies for patients with SDS and other
leukemia predisposition syndromes rely on monitoring hemato-
logic status by serial peripheral blood counts to identify wor-
sening cytopenias and bone marrow examinations to identify
morphologic changes or development of clonal chromosomal
abnormalities11. These tests are insensitive and detect abnorm-
alities that are late signs of impending transformation.
The p53 tumor suppressor pathway is activated by defective
ribosome biogenesis and aberrant protein translation7,12. Somatic
TP53 mutations have been observed in patients with SDS who
develop MDS13, raising the possibility that next-generation
sequencing could be integrated into surveillance for somatic
clones with enhanced leukemia potential. However, TP53 muta-
tions have also been identified in SDS patients without MN14,
suggesting that additional factors must be uncovered before
implementing molecular surveillance as a predictive tool in SDS.
To understand the molecular pathogenesis of MN in patients with
SDS, we characterized the presence and dynamics of somatic
mutations in serial, clinically annotated samples collected pro-
spectively from patients enrolled in the North American SDS
Registry and studied the functional consequences of recurrently
mutated pathways.
In this work, we demonstrate using genomic and functional
studies that SDS patients develop frequent somatic hematopoietic
clones that either bypass or compensate for the germline defect in
ribosome function, and indicate that biallelic TP53 inactivation
mediates clonal transformation through checkpoint inactivation.
Results
Genetic pathways of somatic clonal expansion in SDS. We
investigated genetic pathways that drive somatic hematopoietic
clonal expansion and leukemogenesis in a cohort of 110 patients
with a clinical diagnosis of SDS (Fig. 1a). The clinical char-
acteristics of the cohort are described in Table 1. We first used
whole exome sequencing to identify somatic mutations in bone
marrow aspirate samples and paired fibroblasts from 29 patients
(Fig. 1a and Supplementary Table 1). All 12 patients with MN
had somatic alterations also seen in sporadic MN, including point
mutations in TP53, RUNX1, SETBP1, BRAF, NRAS, and ETNK1,
or recurrent structural alterations involving chromosomes 3, 5, 7,
and 20. As expected, we observed frequent interstitial deletions of
chromosome 20q (8 of 17, 47%) in patients without MN (Sup-
plementary Fig. 1)15. Among these patients without MN, we
further identified recurrent mutations in EIF6 (5 of 17, 29%),
suggesting that disruption of 60S:EIF6 function may drive clonal
expansion in SDS cells. Since we used exome sequencing (mean
target coverage 136×) for gene discovery, it is conceivable that
some candidate somatic mutations were present exclusively below
the threshold of exome sensitivity and were thus not taken for-
ward to cohort-level validation.
We performed targeted validation of candidate gene mutations
in paired bone marrow and fibroblast samples from the whole
cohort, including samples in the exome cohort. We sequenced 55
genes, including those recurrently mutated in the discovery
exome cohort, as well as genes associated with sporadic MN
(Supplementary Table 2). To detect clones present at low
abundance [0.1% variant allele fraction (VAF)], we used a
platform that incorporated duplex unique molecular identifiers,
thereby enabling computational suppression of sequencing
artifacts.
We initially focused our analysis on the most recent sample
from each patient. We detected 327 somatic mutations in 74 of 98
(76%) SDS patients with germline SBDS mutations (median 2
mutations/patient, range 0–21), and no mutations in patients
with SDS-like (SDS-L) disease who have some clinical features of
SDS without disease defining mutations (SBDS, EFL1, DNAJC21,
SRP54). The most frequent somatically mutated genes were EIF6
(60/98, 61%), TP53 (44/98, 45%), PRPF8 (12/98, 12%), and
CSNK1A1 (6/98, 6%) (Fig. 1b). Secondary somatic SBDS
mutations were found in three patients and no other genes were
mutated in more than two patients. Among 74 patients with
somatic mutations, 52 (72.2%) had multiple mutations, frequently
affecting the same gene (Fig. 1c). The most common base
substitution in somatic EIF6 and TP53 variants was a cytosine-to-
thymine (C→ T) transition (Fig. 1d), which is the predominant
mutational signature associated with normal aging hematopoietic
stem cells (HSCs), sporadic clonal hematopoiesis (CH), and
AML16–19.
Clinical factors associated with somatic mutations. Detect-
able TP53 mutations were more common in SDS patients with
germline SBDS mutations and MN than in those without MN
(73.3% versus 39.8%, p= 0.023), while EIF6, CSNK1A1, and
PRPF8 were not associated with MN. In univariate analysis, the
presence of any somatic mutation was associated with older age
(median 12.9 versus 4.7 years, p= 0.0001), as were mutations in
individual genes (TP53, p= 0.0002; EIF6, p= 0.0042; PRPF8, p=
0.0461) (Fig. 1e). Logistic regression adjusting for age, sex, and
the presence of MN showed that age was independently asso-
ciated with the presence of any somatic mutation (OR= 1.1, for
each one-year increase in age, 95% CI 1.1–1.2, p= 0.0017). Fur-
ther, the total number of somatic mutations per patient was
positively associated with age and MN [β(se)= 0.50 (0.2071), p=
0.0165] in a Poisson regression model adjusted for the same
variables.
EIF6 mutations are highly recurrent and specific to SDS.
Across all samples, we identified 265 EIF6 mutations (Fig. 2a), all
of which were in patients with germline SBDS mutations. We did
not detect any EIF6 mutations in control cohorts, including
patients with SDS-L disease (n= 11), patients with other leuke-
mia predisposition disorders (germline GATA2 deficiency syn-
drome, n= 32; telomere biology disorders, n= 5; germline
SAMD9/SAMD9L mutations, n= 5), or adults with sporadic
AML (n= 39). EIF6 truncating mutations were distributed
ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-021-21588-4
2 NATURE COMMUNICATIONS |         (2021) 12:1334 | https://doi.org/10.1038/s41467-021-21588-4 | www.nature.com/naturecommunications
throughout the coding region, whereas missense mutations were
predominantly located in regions encoding conserved secondary
structure (Fig. 2b).
To study the consequences of EIF6 missense mutations, we
generated a homology model that closely matches the
EIF6 structures from Methanocaldococcus jannaschii20, Sacchar-
omyces cerevisiae20,21, and Dictyostelium discoideum22 (Supple-
mentary Fig. 2). To evaluate the impact of mutations on protein
stability, we modeled the effect of each mutation on the energy of
the folded state of EIF6 and compared this to the wild-type
protein (ΔΔGmutation) (Fig. 2c). Missense mutations located at the
EIF6:RPL23 interface were not predicted to destabilize the protein
(median ΔΔGmutation= 2.66 kcal/mol, 95% CI 0.29–3.73) (Fig. 2d
and Supplementary Table 3). In contrast, mutations not located at
binding interfaces (median ΔΔGmutation= 9.83 kcal/mol, 95% CI
7.37–12.37) and those located at the non-60S interface with EFL1
(median ΔΔGmutation= 10.04 kcal/mol, 95% CI 5.79–24.93)
(Fig. 2d) were strongly destabilizing.
EIF6 mutations disrupt 60S:EIF6 function by two mechanisms.
We cloned patient-derived mutations with different predicted
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29 SDS patients with SBDS mutations
- 5 AML
- 7 MDS
- 2 severe bone marrow failure
- 15 without severe BMF/MDS/AML
Discovery cohort
Whole exome sequencing
Paired bone marrow and fibroblasts
110 SDS patients (327 bone marrow samples)
- 98 with SBDS  mutations
- 1 with DNAJC21 mutations
- 11 with clinical SDS (SDS-like, SDS-L)
     - no SBDS/EFL1/DNAJC21/SRP54 mutations
Validation cohort
Targeted, error-corrected sequencing (55 genes)
Paired bone marrow and fibroblasts
identify recurrent 
somatically-mutated genes
Fig. 1 Clinical factors associated with CH in SDS patients. a Schema of genomic analysis. b A co-mutation plot showing somatic mutations in individual
genes as labeled on the left. Mutations are depicted by colored bars and each column represents an individual patient in the indicated study cohort. The
sum total of each event or mutation are tabulated to the right of each plot. c Number of mutations per patient in each of the four most frequently mutated
genes:TP53, EIF6, PRPF8, and CSNK1A. d Base pair substitutions of somatic mutations in TP53 and EIF6. e Total number of somatic mutations by age in
patients with biallelic germline SBDS mutations, based on targeted deep sequencing.
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that expressed wild-type or mutant EIF6 cDNA with a C-terminal
V5-epitope tag under the control of a doxycycline-inducible
promoter. We measured EIF6 protein levels and mRNA expres-
sion after 48 h of doxycycline treatment and found that six
mutants (I13N, R67W, G69S, P73R, A194T, G196R) had reduced
levels of EIF6 protein compared with EIF6WT, despite comparable
abundance of mutant mRNA (Fig. 2e). Mutant EIF6 protein
abundance was increased after treatment with the proteasome
inhibitor MG-132 (Supplementary Fig. 3A). To assess the effect of
destabilizing EIF6 mutations on the functional competency of
SDS hematopoietic stem and progenitor cells, we expressed either
EIF6WT, EIF6I13N, or EIF6A194T in SBDS-deficient human
CD34+ cells and quantified hematopoietic colony formation.
Both myeloid and erythroid colonies were more abundant with
EIF6I13N and EIF6A194T compared with EIF6WT (Supplementary
Fig. 3B). These results indicate that EIF6 missense mutations can
cause functional inactivation via protein destabilization.
The two most common recurrent mutations in the cohort
were EIF6 p.N106S and EIF6 p.R96W, found in 20% and 13%
of SDS patients, respectively. Among patients with somatic
EIF6 mutations, p.N106S was found in 32% and EIF6 p.R96W
in 22%. In the EIF6 homology model, R96W disrupts
hydrogen bonds and is predicted to destabilize the protein
(ΔΔGmutation= 11.3 kcal/mol), while N106S is predicted to be
stable (ΔΔGmutation= 1.12 kcal/mol). Consistent with these
models, the level of EIF6R96W protein was markedly reduced
compared with EIF6WT (Fig. 2f) and the level of EIF6N106S
protein was similar to EIF6WT (Fig. 2e).
Since N106 is highly conserved and located at the interface
between EIF6 and the 60S ribosomal protein RPL23 (Fig. 2g), we
tested the hypothesis that N106S impairs the EIF6:60S interac-
tion. In the homology model, N106S had significantly increased
energy of EIF6:RPL23 binding (ΔΔGbind)23 compared with
mutations not located at the EIF6:RPL23 interface. To directly
analyze the impact of N106S on this interaction, we conducted
sucrose gradient polysome profiling of lysates from cells
expressing V5-tagged EIF6WT or EIF6N106S, followed by western
blotting across the gradient fractions. While EIF6WT was
primarily present in the 60S fractions24,25, EIF6N106S was found
only in the free fractions and was absent from the 60S fractions
(Fig. 2h). To establish whether lack of EIF6N106S binding to 60S
altered protein synthesis, we compared EIF6N106S to EIF6WT and
found that EIF6N106S improved the SDS-associated impairment
of translation as measured by incorporation of O-propargyl-
puromycin into nascent peptides (Supplementary Fig. 3C).
Additionally, EIF6WT was distributed normally in the cytoplasm
and nucleolus21,26 and EIF6N106S was detectable only in the
cytoplasm (Fig. 2i).
To assess the effect of EIF6N106S on colony formation, we
expressed either EIF6WT or EIF6N106S in SBDS-deficient human
CD34+ cells. Comparable to destabilizing mutants, we observed
an increase in the number of myeloid and erythroid colonies with
EIF6N106S compared with EIF6WT (Fig. 2j). Similarly, SBDS-
deficient cells expressing EIF6-N106S displayed increased overall
growth compared to cells expressing EIF6WT (Fig. 2k).
EIF6 and TP53 mutations alleviate p53 activation. SBDS defi-
ciency impairs ribosome assembly and results in reduced abun-
dance of the mature 80S ribosome, concomitant accumulation of
free 60S ribosome subunits27,28, and upregulation of p53-
dependent cellular stress pathways in SDS patient bone mar-
row29 and SDS mouse models8. Somatic mutations that reduce
p53 activation could thus drive selective clonal advantage either
by rescuing the underlying defect in ribosome maturation or by
directly inactivating TP53.
To investigate the effects of EIF6 and TP53 mutations on
ribosome maturation, protein translation, and p53 target gene
activation in SBDS-deficient cells, we introduced shRNAs that
targeted EIF6 or TP53, or a control shRNA targeting luciferase
into primary SDS patient-derived bone marrow fibroblasts
(Supplementary Fig. 4A). Using sucrose gradient polysome
profiling, we found that knockdown of EIF6, but not knockdown
of TP53, resulted in an increased ratio of 80S:60S ribosomal
subunits relative to control (Fig. 3a and Supplementary Fig. 4B).
Consistent with these distinct effects on ribosome maturation,
knockdown of EIF6, but not knockdown of TP53, improved the
SDS-associated impairment of protein synthesis, as measured by
incorporation of O-propargyl-puromycin into nascent peptides
(Fig. 3b and Supplementary Fig. 4C). Despite their different
impact on the SDS ribosome joining defect, knockdown of either
EIF6 or TP53 resulted in reduction of CDKN1A induction in SDS
fibroblasts (Fig. 3c). Together, these results indicate that EIF6 and
TP53 mutations have distinct effects on ribosome joining and
global protein synthesis, but share a common downstream effect
of reducing CDKN1A expression, which is a marker of p53
pathway activation.
Independence of TP53 and EIF6 mutated clones in SDS.
Among SDS patients with TP53-mutated CH, 90.9% (30 of 33)
had concurrent EIF6 mutations, raising the possibility that TP53
and EIF6 mutations cooperate to drive clonal progression. To
distinguish whether TP53 and EIF6 mutations arise in separate
clones or together within the same clones, we performed single
cell DNA sequencing from patients with CH who had multiple
EIF6 and TP53 mutations detected by bulk sequencing.
Using a custom panel covering seven genes implicated in SDS
or sporadic CH and 43 single nucleotide polymorphism (SNP)
loci on chromosomes 7, 17, and 20, we sequenced 33,426 cells
from six patients with CH. The number (Fig. 4a) and VAF
(Fig. 4b) of gene mutations detected by bulk sequencing in each
patient is shown in Fig. 4. Single cell data was analyzed using the
Mission Bio Tapestri Insight platform and mean sample level
allelic dropout (ADO) was 10.1% (95% CI 8.3–11.8%). ADO was
not accounted for computationally during clone identification,
but was taken into account during manual review based on
metrics including genotype quality, read depth relative to parent
clone, and overall clone size. We focused the single cell analysis
only on mutations that were detected using our bulk DNA
Table 1 Patient characteristics.
SDS (n= 99) SDS-like (n= 11)
Age, median (range), years 10.8 (0.3–49.3) 15.6 (2.0–22.3)
Sex, n (%)
Male 61 (61.6) 10 (90.9)
Female 38 (38.4) 1 (9.1)
SDS germline mutation, n (%)
SBDS 98 (98.9) 0 (0)
DNAJC21 1 (1.0)
Myeloid neoplasm, n (%)
AML 8 (8.1) 0 (0)
MDS 7 (7.1) 0 (0)
None 84 (84.8) 11 (100)
Severe bone marrow failure, n (%)
Yes 6 (6.1) 1 (9.1)
No 93 (93.9) 10 (90.9)
Granulocyte-colony-stimulating-
factor, n (%)
Yes 37 (37.4) 0 (0)
No 55 (55.6) 1 (9.1)
Not available 7 (7.1) 10 (90.9)
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sequencing platform; we did not make any de novo variant calls
from the scDNA-sequencing data. Genotyping was successful for
84.4% of all targeted mutations that were observed by bulk DNA
sequencing and undetected mutations were restricted to low
abundance clones (median VAF 0.0032, range 0.0022–0.0087).
Using this single cell approach, we found that somatic mutations
were almost always present in independent clones: among the 50
clones we identified: 24 had a sole EIF6 mutation, 21 had a sole
TP53 mutation, and 3 had a sole CSNK1A1 mutation (Fig. 4c).
One patient (SDS-026) had a clone with concurrent mutations
in TP53 and EIF6, where TP53 p.R248Q defined the founding
clone and EIF6 p.S86A defined a subclone. In another patient
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(SDS-072), we observed a founding clone with EIF6 p.M1T and a
subclone with TET2 p.E227* mutation.
Clonal hematopoiesis in SDS patients. CH in individuals without
germline predisposition is associated with older age and usually
involves single mutations affecting DNMT3A, TET2, or ASXL119,30.
Among 83 SDS patients without a MN diagnosis, 60 (72%) had
detectable CH, 40 of whom had more than one mutation (median
3, range 1–21). Two of these patients had CH defined by clonal
cytogenetic alterations in the absence of point mutations. Recurrent
mutations in EIF6 (49 of 83, 59.0%), TP53 (33 of 83, 39.8%), PRPF8
(9 of 83, 10.8%), and CSNK1A1 (6 of 83, 7.2%) composed 96.9% of
all somatic mutations, while typical CH mutations such as
DNMT3A, TET2, or ASXL1, were rare (n= 1 for each) (Fig. 5a).
CH mutations were present at low abundance irrespective of the
affected gene, including EIF6 (median VAF 0.0047, range
0.002–0.282), TP53 (0.0044, range 0.002–0.193), PRPF8 (0.0052,
range 0.002–0.375), and CSNK1A1 (0.0053, range 0.002–0.100)
(Fig. 5b). CH was detectable in 27 of 46 patients (59%) 10 years old
and younger, 24 of 27 patients (89%) 11–20 years old (89%) and 10
of 10 patients (100%) 21 years or older (Fig. 5c).
To assess the onset, persistence, and dynamics of CH
mutations over time, we sequenced 208 serial samples from 49
SDS patients with CH (median 4 samples, range 2–11). We first
analyzed serial samples from six patients who had developed CH
prior to 10 years of age and for whom the initial sample was
obtained at age 3 years or younger. In five cases, stable CH
developed at older ages (3–10 years old), while in one case (SDS-
034), a stable EIF6mutation was detected at time of first sampling
at age 2 (Fig. 5d). Among six older patients whose last sample was
obtained between ages 15 and 31 years, stable CH was detectable
at the earliest available time point, 5–10 years prior (Fig. 5e).
Among all 49 patients with CH who had serial samples, most
mutations were detected across multiple timepoints. Among
persistent clones, we measured the mutation allele burden across
serial timepoints and found that most clones remained stable at low
VAF over time, with little change in relative abundance between
initial detection and the most recent sample (Fig. 5f). None of the
patients with CH involving EIF6 or TP53 had severe marrow failure
despite the higher median age of the CH group compared to the
group who developed severe marrow failure (Fig. 5g).
Clonal evolution and development of leukemia. The diagnosis
of MN was associated with the presence of somatic TP53 muta-
tions. However, TP53 mutations were common in SDS clonal
hematopoiesis and most were stable without hematologic pro-
gression across years of observation or detected only at a single
timepoint. Therefore, we sought to identify additional genetic
characteristics of TP53 mutated leukemias that might enable
distinction of CH clones with high-risk of transformation from
those likely to remain clinically stable.
We analyzed exomes from seven patients with TP53-mutated
MN for allelic imbalances at the TP53 locus by evaluating the total
copy ratio (tCR) and SNP VAF across chromosome 17. We found
that all seven patients had biallelic alteration of TP53, occurring by
one of three mechanisms based on the number of TP53 mutations
(1 vs. 2 or more) and the presence of TP53 deletion or copy-
neutral loss of heterozygosity (CN-LOH). We observed 4 cases
with monoallelic TP53 mutations and 17p CN-LOH, 1 with
monoallelic TP53 mutation and 17p deletion, and 2 with biallelic
TP53 mutations (Fig. 6a). We next determined the fraction of
clonal cells in which each TP53 mutation was present, which
defines its cancer cell fraction (CCF)31,32. In each case, the TP53
mutations were present at high CCF, indicating that they were
likely present in all cells of the leukemic clone (Fig. 6b). Among
TP53 mutated MN, 3 of 7 also harbored somatic mutations in
typical myeloid drivers, including subclonal mutations in NRAS
(n= 2), KRAS, or PTPN11. Somatic mutations in genes encoding
effectors of RAS/MAPK signaling (NRAS, KRAS, PTPN11, CBL,
FLT3, RIT1, KIT) were rarely present in samples from patients
without morphologic transformation.
In 4 of 15 patients with morphologically defined MN, we did
not detect somatic TP53 mutations. All four of these patients had
MDS. In two, we identified mutations in canonical myeloid driver
genes, including one with SETBP1, BRAF, NRAS, and KRAS
mutations and one with ASXL1 and ETNK1 mutations. Of the
remaining two patients without point mutations, one had deletion
of chromosome 7q and the other was diagnosed with MDS based
on morphologic dysplasia without cytogenetic abnormalities or
increased blasts.
Biallelic TP53 alterations identify leukemic subclones. Early
detection of leukemia-associated genetic alterations could identify
clones with increased leukemic potential prior to clinical trans-
formation. We therefore sought to define the latency between
detection of these mutations and clinical progression in a patient
who developed AML despite having stable blood counts and no
morphologic evidence of MN on bone marrow examinations
during standard clinical surveillance. Using exome sequencing,
we identified a TP53 p.C242F mutation with CN-LOH in the
AML sample (Fig. 6a), then used deep, error-corrected
Fig. 2 EIF6 somatic missense mutations alter EIF6 protein stability or function to improve cell fitness. a Types of somatic EIF6 mutations. b Number and
location of EIF6 mutations according to variant type. c Impact on the calculated energy of the folded state (ΔΔGmutation) of EIF6 missense mutations.
Mutant residue colored according to ΔΔG value. d ΔΔGmutation of 12 EIF6 missense mutations located at the RPL23-binding interface versus 85 other EIF6
missense mutations located in the remainder of EIF6. Boxes center around the median and span the 25th and 75th percentiles, whiskers extend to the 10th
and 90th percentiles. p value calculated using unpaired two tailed t-test. e Relative levels of EIF6 mRNA using a V5-specific qPCR primer (top panel) and
V5 immunoblot from K562 cells 48 h after doxycycline treatment (bottom panel). Data shown is representative of three independent experiments. f Left
panel: In silico modeling of EIF6-R96W. Right panel: V5 and VCL immunoblots of K562 cells with inducible EIF6-R96W versus V5-wild type EIF6 48 h after
doxycycline treatment. Data shown is representative of three independent experiments. g Left panel: Change in the energy of binding (ΔΔGbind) of
missense mutations at RPL23 interface. Mutant residues are colored according to ΔΔGbind. Right panel: In silico modeling of EIF6 N106S mutation. h V5,
EIF6, and RPL3 immunoblots of sucrose gradient fractions from polysome profiles of doxycycline-treated K562 cells expressing V5-EIF6-WT or V5-EIF6-
N106S. Data shown is representative of three independent experiments. i Immunofluorescence of V5-EIF-WT or V5-N106S-EIF6 protein in SDS patient-
derived fibroblasts, V5 (green), fibrillarin (red), and DAPI (blue). Right panel: quantification of V5 nucleolar signal from four independent experiments.
Error bars represent the mean ± standard deviation. Scale bar= 10 μm. j Quantification of colony forming units from sorted CD34+ transduced with
shSBDS-GFP and either EIF6-WT-RFP or EIF6-N106S-RFP plated in triplicate. Data shown are representative of three independent experiments. Error bars
represent the mean ± standard deviation. k Competitive growth of doxycycline inducible-shSBDS in K562 cells (Supplementary Fig. 3D) transduced with
either EIF6-WT-RFP or EIF6-N106S-RFP after indicated time from doxycycline treatment (n= 3 technical replicates, representative of three biological
replicates). Error bars represent mean ± standard deviation.
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sequencing to quantify mutation allele burden in bulk DNA
across serial samples obtained prior to transformation. The TP53
p.C242F mutation was first detectable at low abundance (VAF=
0.17%) 4.5 years prior to transformation (Fig. 6c). In addition to
this pre-leukemic mutation, we also identified 17 additional
mutations from four samples across 6.6 years of surveillance (ages
16–22), including TP53 (n= 7), EIF6 (n= 7), CSNK1A1 (n= 2),
PRPF8 (n= 1), and SBDS (n= 1). Throughout surveillance, the
pre-leukemic TP53 p.C242F clone was indistinguishable from
other TP53-mutated clones based on low VAF and relative sta-
bility across serial samples.
Bulk sequencing cannot reliably identify interval acquisition of
TP53 allelic imbalance in small clones. We therefore sequenced
20,214 single cells across three samples obtained 6.5, 4.5, and 0.5
years before clinical transformation in order to identify the
earliest evidence of TP53 CN-LOH. All TP53 mutations detected
by bulk sequencing were also observed using single cell DNA
sequencing, but only the TP53 p.C242F clone displayed evidence
of clonal evolution with TP53 LOH. Concordant with bulk-
sequencing data, the TP53 p.C242F was first detectable 4.5 years
prior to development of AML (Fig. 6d). The TP53 p.C242F clone
was initially present at low abundance (0.1%), with a balanced
proportion of the heterozygous founding clone and the homo-
zygous (CN-LOH) progression subclone. Subsequently, the CN-
LOH subclone expanded selectively over the following 4 years
prior to subsequent transformation. Other stable TP53 mutations,
including the most abundant p.R248W and p.L257R clones,
defined independent clones and remained in the monoallelic state
across 6.5 years of surveillance. These data indicate that
development of TP53 LOH events can precede frank transforma-
tion by several years and that single cell DNA sequencing enables
detection of small clones defined by TP53 LOH events.
Discussion
We found that germline SBDS deficiency establishes a global
fitness constraint that drives selection of somatic clones via two
pathways with distinct mechanisms and different clinical con-
sequences. A compensatory pathway with limited leukemic
potential, mediated predominantly by EIF6 inactivation, enhances
clone fitness by ameliorating the SDS ribosome defect. A mala-
daptive pathway with enhanced leukemic potential, driven by
TP53 inactivation, subverts normal tumor suppressor checkpoints
without correcting the ribosome defect (Fig. 7).
Through analysis of serial samples collected in children and
young adults with SDS, we demonstrate that somatic clones are
infrequent in the first several years of life, but approach ubiquity
in the second decade. Many patients had multiple somatic
mutations, but this high somatic mutation burden typically
reflects a composite of multiple, genetically distinct and inde-
pendently arising clones rather than a single clone with complex
subclonal evolution. Most of these somatic clones in SDS patients
carried a mutation in one of only four genes (EIF6, TP53, PRPF8,
and CSNK1A1), and rarely involved genes commonly mutated in
age-related CH (DNMT3A, TET2, ASXL1). These results provide
genetic evidence that germline SBDS deficiency causes a global,
disease-specific HSC fitness constraint that drives parallel devel-
opment of somatic CH at an early age.
We show that somatic EIF6mutations are common in SDS and
that they cause functional compensation of SBDS deficiency by
rescuing the SDS ribosome joining defect, improving translation,
and reducing p53 activation. Using structural modeling and
functional studies, we demonstrate that EIF6 missense mutations
exert these effects by either disrupting the binding interaction
between EIF6 and the 60S subunit or by destabilizing the EIF6
protein. Our findings in SDS patients are consistent with prior
studies in yeast, where mutations in the EIF6 homolog TIF6 were
shown to attenuate the slow growth phenotype seen with deletion
of the SBDS homolog SDO127. Notably, several residues that we
found to be recurrently mutated in SDS patients, including p.G14,
p.G105, and p.N106, are invariant between human and Archaea
and were found in a yeast genetic screen to cause reduced affinity
for 60S subunits. Our study contrasts with a mouse model of Eif6
haploinsufficiency in non-SDS cells, where reduced Eif6 levels
















































































































Fig. 3 EIF6 and TP53 mutations attenuate p53 activation via different
mechanisms. a Quantification of 80S:60S ratio from polysome profiles in
SDS patient-derived primary fibroblasts transduced with shRNAs targeting
luciferase, EIF6 (left panel) or TP53 (right panel). b OP-Puro incorporation
in primary SDS patient-derived fibroblasts transduced with shRNAs
targeting luciferase, EIF6 (left panel) or TP53 (right panel). c Relative
CDKN1A expression in SDS patient-derived fibroblasts transduced with
either shLUC control or shEIF6 (left panel) and shTP53 (right panel). Error
bars represent mean ± standard deviation of three technical replicates
representative of two to three independent experiments. p value calculated
using unpaired two-tailed t-test.
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Normalization of germline-encoded hematopoietic defects
through somatic reversion has been observed in inherited bone
marrow failure syndromes34–36. In SDS, we found that somatic
mutations mitigate the cellular consequences of SBDS deficiency
via compensatory mechanisms without direct reversion or cor-
rection of the causative genetic lesion. Specifically, highly recur-
rent functional inactivation of EIF6 via multiple genetic
mechanisms (point mutations and interstitial del(20q)) indicates
that normalizing the functional ratio of SBDS:EIF6 protein in
SDS hematopoietic cells enhances competitive fitness by
improving ribosome maturation and translational capacity. EIF6
alterations are not associated with leukemic transformation or
TP53 co-mutation within the same cell and were not found in
patients with severe bone marrow failure, suggesting that func-
tional correction of germline-encoded cellular defects may drive
enhanced fitness of somatic clones without altering normal
pathways of differentiation or tumor suppression. Our results
support EIF6 as a potential therapeutic target in SDS patients,
since pharmacologic inactivation of EIF6 could mimic genetic
inactivation of EIF6, thereby reducing leukemia risk and
improving hematopoietic function in SDS patients.
The presence, number, persistence, and allele abundance of
somatic TP53mutations were not predictive of imminent leukemia
risk in SDS patients with CH. Biological and clinical heterogeneity
among different hotspot TP53 mutations has been reported37, but
we were unable to evaluate this question due to sample size lim-
itation. Our results indicate that progression of TP53-mutated
clones is driven by development of biallelic alterations of the TP53
locus via deletion, CN-LOH, or point mutation, consistent with









































































































































































































































































































































































































































































































































































Fig. 4 Independence of TP53 and EIF6mutated clones in SDS patients. a Number of somatic mutations detected in each patient by bulk DNA sequencing.
b corresponding VAF of TP53 (red), EIF6 (blue) or other (black) mutation. c Clonal hierarchy of mutations determined by single cell sequencing amongst
six patients with SDS. Each row represents a unique clone or subclone and the frequency of each clone is indicated to the left. Columns reflect the genotype
status of each mutation in each clone, and all depicted clones have complete genotyping at all loci. The y-axis indicates single cell VAF from 0 to 1, where 0
is absent, 0.5 is heterozygous mutation, and 1 is homo/hemizygous. Each dot reflects a single cell, colored according to gene mutation, TP53 (red), EIF6
(blue), CSNK1A1 (black) and the frequency distribution of the data points reflected by shaded violin plots.
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found that SDS patients can develop multiple, independent TP53-
mutated clones and that serial monitoring by bulk sequencing fails
to distinguish clinically significant subclonal changes in TP53
allelic state. These findings suggest that integration of single cell
DNA sequencing into surveillance strategies might identify
patients with high risk clones prior to clinical transformation. In
conclusion, our study elucidates biological mechanisms driving
distinct pathways of CH in SDS and defines a framework for
rational surveillance. An improved ability to identify patients with
high risk of developing leukemia has the potential to improve
clinical outcomes by enabling preemptive intervention with cura-
tive therapies, such as allogeneic transplantation.
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Fig. 5 CH in SDS patients. a Frequency of mutations in the indicated genes among the 58 SDS patients with CH. b VAFs in the indicated genes among
378 samples from SDS patients with clonal hematopoiesis. Horizontal lines within boxes indicate median VAF. Boxes center around the median and span
the 25th and 75th percentiles with whiskers and outliers defined by the Tukey method. c Proportion of patients in the study cohort per decade of age with
detectable CH, where CH was defined as the presence of a recurrent somatic clonal genetic alteration. d, e Shown is the VAF of each somatic EIF6 (blue),
TP53 (red) or CSNK1Amutation (black) from d six patients who developed clonal hematopoiesis in the first decade of life and e six patients who were found
to have clonal hematopoiesis in their second or third decade of life. Arrows indicate timing of sample acquisition. Points represent the VAF for detected
mutations f, Fold change in VAF of all somatic EIF6 (blue) and TP53 (red) mutations from time of first detection to time of most recent detection in 23
patients with CH. Boxes center around the median and span 25th and 75th percentiles with whiskers and outliers defined by the Tukey method. g Ages of
patients at diagnosis of six patients with severe bone marrow failure (BMF), 15 patients with myeloid neoplasm (MN), or no BMF/MDS with (59 patients)

































































































































































Cancer Cell Fraction (CCF)
SDS-048: year 6 of surveillance









































































































































































































Fig. 6 Biallelic TP53 inactivation and myeloid neoplasia in patients with SDS. a Total copy ratio (tCR, denoted in black) and phased SNP-VAF (denoted in
red/blue) across chromosome 17. b Cancer cell fraction of somatic TP53 mutations in seven patient samples analyzed in panel a. c Shown are the
clinicopathologic status and VAF of somatic TP53 (red), EIF6 (blue), and CSNK1A (black) mutations from bulk sequencing of serial samples from SDS-048,
a patient with SDS who progressed to AML. d Single cell sequencing demonstrating clonal hierarchy from SDS-048 during serial surveillance prior to
development of AML. Each row represents a unique clone or subclone and the frequency of each clone is indicated to the left. Columns reflect the genotype
status of each mutation in each clone, and all depicted clones have complete genotyping at all loci. Y-axis indicates single cell VAF from 0 to 1, where 0 is
absent, 0.5 is heterozygous mutation, and 1 is homo/hemizygous. Each dot reflects a single cell, colored according to gene mutation, TP53 (red), EIF6
(blue), CSNK1A1 (black) and the frequency distribution of the data points reflected by shaded violin plots. Shown on the right is a time course indicating
dynamics of the pre-leukemic p.C242F mutated clone and two independent TP53-mutated clones that did not transform.
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Methods
Cell culture. Human leukemia cell lines (K562, isogenic K562 with a CRISPR-HDR
corrected TP53 allele38), kindly provided by Benjamin Ebert (Dana Farber Cancer
Institute) were maintained in RPMI media (Gibco, 11875-119) supplemented with
10% FBS, penicillin and streptomycin (Gibco). Primary cultures of bone marrow
fibroblasts were established and maintained in Chang D media (Irvine Scientific,
T105). Mobilized peripheral blood CD34+ and bone marrow mononuclear cells
were maintained in GMP SCGM Serum-free Media (Cellgenix, 20802–0500)
supplemented with 100 ng/mL hSCF (Peprotech, 300-07), hTPO (Peprotech, 300-
18), hFLT3-L (Peprotech, 300-19), and for bone marrow mononuclear cell culture,
20 ng/mL of IL-3 (R&D systems 203-IL-010/CF) was added. All cells lines were
cultured at 37 °C under 5% CO2 and routinely screened for mycoplasma39.
Colony formation assays. For methylcellulose colony formation assays, G-CSF
mobilized peripheral blood CD34+ cells (Fred Hutch CCEH Core B) were
resuspended in GMP SCGM Serum-free Media plus cytokines noted above
(Cellgenix, 20802-0500) and allowed to recover for 36 h. Cells were transduced
with indicated lentiviral vectors and for CD34+ cells were sorted using BD
FACSAria (BD biosciences) to obtain double-positive population. Doublets were
excluded using standard methods of FSC/FSC-A doublet exclusion and then dis-
tinctly positive RFP and GFP cells were selected based on comparison to
untransduced CD34+ cells(gating shown in Supplementary Fig. 5A). Then 1750
CD34+ cells were added to 3.5 ml of methylcellulose (Stem Cell Technologies,
H4434). One milliliter was plated in triplicate wells of six-well Smartdishes (Stem
Cell Technologies, 27370). After 12 days of growth at 37 °C/5% CO2, colonies were
imaged, results blinded and then counted using STEMVision (Stem Cell Tech-
nologies). Counts were averaged for triplicate wells.
Plasmids, cloning and site-directed mutagenesis. Gateway vectors containing
EIF6 cDNA were obtained from the Harvard Plasmid Repository in closed format
(clone ID HsCD00044644) or open format (clone ID HsCD00041550). Site-
directed mutagenesis was performed using the NEB Q5 site-directed mutagenesis
kit according to manufacturer instructions (New England Biolabs, E0554S) using
primers listed in Supplementary Table 4. Gateway cloning was performed using LR
clonase (Invitrogen, 11791-020) according to manufacturer instructions. Closed
constructs were cloned into pRRL-SFFV-gwdest. Open constructs were cloned into
constructs with V5 C-terminal tags: tetracycline inducible pLIX-403 or constitutive
expression pLX304. pLIX-403 and pLX30440 were gifts from David Root (pLIX-403
is Addgene plasmid #41395, pLX304 is Addgene plasmid #25890). Tetracycline-
inducible short hairpin RNAs targeting SBDS were made by annealing oligos and
ligating with T4 ligase (New England Biolabs, M0202) into AgeI and EcoRI-
digested Tet-pLKO-puro. Tet-pLKO-puro was a gift from Dmitri Wiederschain
(Addgene plasmid #21915)41.
Immunofluorescence. Primary bone marrow fibroblasts from SDS patients were
grown on coverslips in a six-well plate at a density of 3 × 105 cells/coverslip for
24 hs. Cells were washed with PBS (Gibco), fixed with 4% (w/v) paraformaldehyde
(MilliporeSigma) for 10 min at room temperature, washed three times with PBS,
permeabilized with 0.2% Triton X-100 (VWR) for 5 min at room temperature,
washed three times with PBS, and blocked for 30 min at room temperature in
solution with 3% BSA (MilliporeSigma) before 30 min incubation with primary
antibody at room temperature (Fibrillarin, Cell Signaling, 2639, clone C13C3, Lot:
2, 1:1000), (V5, Medical and Bio Labs, M215-3, clone OZA3, Lot: 003, 1:10,000).
Coverslips were washed three times with 1% Triton (VWR) in PBS before incu-
bation with secondary antibody (AlexaFluor 594 donkey anti-rabbit IgG (Fisher
Scientific, A21207, Lot: 1827674, 1:1000) or AlexaFluor 488 donkey anti-mouse
(Life Technologies, A-21202, Lot: 1820538, 1:1000)). Cells were mounted with
mounting medium containing DAPI (Vector Laboratories, H-1200) for nuclear
counterstaining and were imaged with a Nikon Eclipse 90i microscope.
Polysome profiling. Ribosomal subunits were separated by sucrose density gra-
dients as described28. Briefly, 4 × 106 fibroblasts (80% confluence) or 2.5 × 106
K562 (1 million/mL) were treated with cycloheximide at final concentration of
100 µg/mL for 10 min at 37 °C before harvesting. Cells were then lysed in lysis
buffer (20 mM HEPES pH 7.4, 100 mM KCl, 10 mM MgCl2, 1% [w/v] NP-40, 1%
[w/v] deoxycholate, 100 µg/mL cycloheximide, 1 mM DTT, 200 µg/mL heparin,
with complete EDTA-free protease inhibitors (Roche), 1.4 µM pepstatin A, and
40 U/mL Rnasin (Promega N2115) and incubated for 10 min on ice. Lysates were
cleared in a microcentrifuge at 4 °C. Equal amounts were applied to a 5–50% (w/v)
sucrose gradient in gradient buffer (10 mM HEPES pH 7.4, 50 mM KCl, 5 mM
MgCl2, 100 µg/mL cycloheximide) and centrifuged (Beckman SW55.1 rotor at
246,000 × g for 1 h and 15 min at 4 °C). The sucrose gradient was made using a
Biocomp Gradient Master. Centrifugation samples were unloaded using a Brandel
gradient fractionator, polysome profiles detected at 254 nM absorbance and area
under the curve for 80S and 60S peaks quantitated using Peakchart version 2.08
(Brandel). 0.1 mL fractions collected into Laemmli sample buffer and separated on
SDS–PAGE gels and transferred to PVDF membranes for immunoblotting.
qRT-PCR analysis of transcription. RNA was isolated following manufacturer’s
instructions for RNeasy Plus Mini Kit (QIAGEN Inc., 44134). RNA was eluted in
30 μl of water. We used 200 ng–1 μg of RNA for reverse transcription with
Superscript III First Strand Synthesis using oligo-dT primer (Invitrogen,
18080051). For qPCR analysis, cDNAs were diluted threefold in MilliQ water.
Quantitative PCR was performed with iTaq Universal SYBR Green Supermix (Bio-
Rad, 1725125). The linear range of amplification for each primer pair was con-
firmed by serial dilution of genomic DNA from K562 cells. Reactions were carried
out in triplicate in a 7500 Fast real-time PCR System (Applied Biosystems) and
analyzed using the ΔΔCT method42. The primer sequences are shown in Supple-
mentary Table 4.
Virus production and titration. Transfection of 293T cells (obtained from
Dr. David Williams’ laboratory) was performed as described43. Lentiviral vector
supernatants were generated by cotransfecting lentiviral transfer vectors (pRRL-
SFFV-gwdest, pLIX-403 (Addgene plasmid #41395), pLX304 (Addgene plasmid
Fig. 7 TP53 and EIF6 mutations define distinct pathways of somatic clonal progression and distinguish leukemia predisposition in SDS. Germline
context drives separate compensatory and maladaptive somatic pathways of clonal evolution in patients with SDS. Germline SBDS mutations result in
ribosomal stress which activate TP53 checkpoint pathways and promote bone marrow failure. EIF6 mutations alleviate the underlying ribosome maturation
defects which reduces p53 checkpoint activation and improves cell fitness. TP53 mutations eliminate checkpoint pathways to improve relative fitness
without improving the underlying ribosomal abnormalities, and promote the development of myeloid malignancies.
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#25890), tet-pLKO-puro (Addgene plasmid #21915), SMARTvector-human-
shEIF6 (Dharmacon V3SH11243-07EG3692), SMARTvector-hCMV-shTP53-
TurboGFP (Dharmacon V3SH11243-00EG7157), SMARTvector-hCMV-shTP53-
TurboRFP (Dharmacon V3SH11243-07EG7157), pL40C.SFFV.eGFP.miR30N.
PRE-shLUC44 (CGCTGAGTACTTCGAAATGTC) or pL40C.SFFV.eGFP.
miR30N.PRE-shSBDS with packaging plasmids psPAX2 (Addgene plasmid
#12260) and pMD2.G (Addgene plasmid #12259) using PEI reagent (Polysciences
#23966-2). Supernatants were collected, filtered through a 0.45 µm membrane
(ThermoFisher, 165-0045), and subsequently concentrated by ultracentrifugation
at 10,000 rpm for 10 h in a Beckmann XL-90 centrifuge using SW-28 swinging
buckets. To determine the titer, HT1080 cells (obtained from Dr. David Williams’
Laboratory) were infected with the virus in the presence of 8 µg/ml polybrene
(Santa Cruz, SC134220) and analyzed 48 h post-transduction by fluorescence-
activated cell sorting for GFP expression.
Growth competition assay. K562 TP53-corrected cells containing puromycin
selectable doxycycline inducible shRNA-targeting SBDS (target sequence
GCTTGGATGATGTTCCTGATT) were transduced with lentivirus encoding
constitutively expressed EIF6-RFP mutant or wild-type constructs as noted. After
48 h, cells were admixed at a ratio of 1:1 and subjected to flow cytometry (gating
shown in Supplementary Fig. 5B) at indicated times on a Fortessa HTS flow
cytometer (BD Biosciences). Doxycycline (Clonetech 1 µg/mL) was refreshed daily
and cells were maintained in puromycin (Mirus, 2 µg/mL) throughout the
experiment. Analysis was performed at indicated timepoints with FacsDIVA
software (BD Biosciences). Doublets were excluded using standard methods of
FSC-H/FSC-A doublet exclusion and then the number of distinctly positive RFP
cells analyzed based on comparison to untransduced cells.
Immunoblotting. Cells were lysed in RIPA buffer (MilliporeSigma) supplemented
with protease inhibitors (Inhibitab, Roche). Protein concentrations were deter-
mined by colorimetric assay (BCA Protein, Thermo Fisher Scientific), and
20–40 μg of protein was loaded on 12% SDS–PAGE gels and blotted on a PVDF
membrane (MilliporeSigma, IPVH00010). The membranes were blocked with 5%
nonfat dry milk (VWR) diluted in Tris-buffered saline (Teknova, T1680) with 1%
Tween-20 (VWR, M147-1L). Primary antibodies SBDS45 (homemade, B1872,
1:10,000), GAPDH (Cell Signaling, 2118, clone 14C10, Lot: 10, 1:1000), eIF6 (Cell
Signaling, 3833, clone D16E9, Lot: 1, 1:1000), p53 (Calbiochem, OP43, clone DO-1,
Lot: 3182624, 1:1000), RPL3 (Abcam, ab241412, polyclonal, Lot: GR3251648-4,
1:1000), Ubiquitin (Cell Signaling, 3933, polyclonal, Lot: 6, 1:1000), V5 tag (Abcam,
ab15828, polyclonal, Lot: GR3265659-1, 1:1000), Vinculin (Invitrogen, 700062,
clone 42H89L44, Lot: 2090723, 1:5000), were incubated overnight at 4 °C. After
washing with TBS-T, membranes were incubated with HRP-conjugated secondary
antibodies ECL anti-rabbit IgG (GE Healthcare, NA934V, Lot: 16897770, 1:10,000;
Cell Signaling, 7074, Lot: 26, 1:10,000) and ECL anti-mouse (GE Healthcare,
NA931V, Lot: 16895895, 1:10,000) and developed using SuperSignal West Pico
Chemiluminescent substrate (Thermo Fisher Scientific, 34094). Detection of bands
was conducted in the Amersham Imager 600 (GE Healthcare).
OP-Puro incorporation. OP-Puro (Medchem Source; Life Technologies, C10459;
50 μM final concentration) was added to the culture medium for 3 h and incubated
in a 37 °C incubator. Cells were removed from wells and washed twice in Ca2+ and
Mg2+ free phosphate buffered saline (PBS)+ cycloheximide. Cells were fixed in
0.5 ml of 1% paraformaldehyde in PBS for 10min, then permeabilized in PBS
supplemented with 3% fetal bovine serum and 0.1% saponin for 5 min at room
temperature. The azide-alkyne cycloaddition was performed using the Click-iT Cell
Reaction Buffer Kit (Life Technologies, C10458) and azide conjugated to Alexa Fluor
647 (Life Technologies, C10458) at 5 μM final concentration for 30min. The cells
were washed twice in PBS and passed through a filter top tube prior to being
analyzed by flow cytometry using a Fortessa HTS flow cytometer (BD Biosciences).
Doublets were excluded using standard methods of FSC-H/FSC-A doublet exclusion
and then distinctly positive RFP or GFP cells were selected based on comparison to
control cells (gating shown in Supplementary Fig. 5C). Mean fluorescence intensity
of positive cells was quantified using FlowJo (FlowJo LLC) version 10.3.0.
Statistical analysis. Graphpad Prism version 8 and SAS 9.4 (SAS Institute, Cary,
NC) was used to analyze results and create graphs. Fisher’s exact test is used to assess
the association between presence of mutations and patient characteristics. Wilcoxon
rank sum test is used to assess the association between number of mutations and
patient characteristics. Results are considered significantly associated with outcome if
p-values < 0.05 and marginally associated with outcome if p < 0.10.
Patients and samples. Subjects provided written informed consent for protocols
approved by the institutional review boards of Boston Children’s Hospital and
Cincinnati Children’s Hospital, in accordance with the Declaration of Helsinki’s
Ethical Principles of Medical Research Involving Human Subjects. All subjects or
their guardian provided written informed consent prior to their participation in the
study. This informed consent included permission to publish. Clinical criteria for
SDS diagnosis were as described in consensus guidelines46.
DNA extraction. DNA was extracted from patient samples and patient fibroblasts
using the QIAamp DNA Blood Mini kit (Qiagen, 51104) according to manu-
facturer instructions.
Single-cell DNA sequencing. We designed a custom panel covering seven genes
implicated in SDS or sporadic clonal hematopoiesis and 43 single nucleotide
polymorphism loci on chromosomes 7, 17, and 20 for ADO determination (Sup-
plementary Table 5). Libraries were generated from cyropreserved or fresh bone
marrow mononuclear cells with the Mission Bio Tapestri Single-cell DNA custom
Kit according to manufacturer’s instruction (Mission Bio) with the following
modifications: concentration of cell input was increased by 15% to 3500–4500 cells
per microliter and library PCR cycles were increased by one cycle. Libraries were
pooled in equimolar concentration and sequenced on a NovaSeq (Illumina) on a
150 base pair paired end run. FASTQ files were processed using the Tapestri
Pipeline for adapter trimming, alignment, barcode correction, cell finding, and
variant calling. Loom files that were generated by the Tapestri Pipeline using
GATK-based haplotype calling and subjected to the following genotyping criteria:
total read count (depth, DP) ≥ 10, alternative allele count ≥ 3, alternate single cell
allele fraction ≥ 30%. Only variants defined based on duplex UMI bulk sequencing
data were included in this analysis; no de novo variant calling was performed using
the scDNA sequencing data (Tapestri Insights 2.2, Mission Bio). To quantify the
technical dropout, we defined the proportion of targeted mutations, which were
defined as those (1) present in the bulk sequencing and (2) located in designable
amplicons, for which genotyping was successful. To quantify ADO, we evaluated
informative SNPs within exonic targets and a series of informative intergenic SNPs
included in our design. For each variant, we determined the ADO by dividing the
number of cells with homozygous reference or variant genotype by the number of
cells with heterozygous genotype. The mean sample-level ADO was 10.1% (95% CI
8.3–11.8%) and mean site-specific ADO rate was 10.4% (95% CI 9.8–11.9%).
Whole exome sequencing. Prior to library preparation, DNA was fragmented
(Covaris sonication) to 250 bp and further purified using Agentcourt AMPure XP
beads. Size-selected DNA was then ligated to specific adapters during automated
library preparation (SPRIworks, Beckman-Coulter). Libraries were pooled and
sequenced on an Illumina MiSeq to estimate the concentration based on the
number of barcode reads per sample). Library construction is considered successful
if the yield is ≥250 ng. Libraries were pooled in equal mass to a total of 750 ng for
SureSelect Human All Exon V5 enrichment using the Agilent SureSelect hybrid
capture kit. Captures were further pooled and sequenced on HiSeq2500 or
HiSeq3000 (Illumina). Pooled sample reads were de-convoluted (de-multiplexed)
and sorted using the Picard tools47. Reads were aligned to the reference sequence
b37 edition from the Human Genome Reference Consortium using “bwa aln”
(http://bio-bwa.sourceforge.net/bwa.shtml) using the following parameters “-q 5 -l
32 -k 2 -o 1” and duplicate reads were identified and removed using the Picard
tools. The alignments were further refined using the GATK tool for localized
realignment around indel sites. Recalibration of the quality scores was also per-
formed using GATK tools48,49. Metrics for the representation of each sample were
generated on the unaligned reads after sorting on the barcode. Fingerprinting
analysis was performed using 44 polymorphic loci to identify if the aggregation
pairing strategy was performed appropriately. Picard Tools GenotypeConcordance
was used to calculate the concordance that a given test sample matches the sample
being considered. This was performed on all pairwise combinations of samples in
the cohort. The output of the pairwise comparisons was then mapped to a con-
cordance matrix, where concordance values above 4 standard deviations of the
median concordance value for the cohort indicated a high likelihood that the
samples match. Samples can match for reasons other than being from the same
individual, so potential matches are manually reviewed where applicable.
For bone marrow samples, median of mean target coverage= 136×, range
101–198×. Mutation analysis for single nucleotide variants (SNV) was performed
using MuTect v1.1.4 and annotated by Variant Effect Predictor (VEP). We used the
SomaticIndelDetector tool that is part of the GATK for indel calling. VEP v79 is
used for annotating the variants. MuTect was run in paired mode with bone
marrow aspirate and cultured fibroblast samples from each subject. Variants that
affected protein coding regions underwent further filtering/classification based on
frequency in the gnomAD, ESP, and COSMIC (version 80) databases. Variants that
affect protein coding regions were flagged as “REVIEW_REQUIRED”, if the
frequency of the variant is ≤1% in all gnomAD and ESP populations or if the
frequency of the variant is >1% and ≤10% in all gnomAD and ESP populations and
present in “COSMIC” database at least two times. Variants were flagged as
“NO_REVIEW_GERMLINE_FILTER” if the frequency of the variant is between
1% and ≤10% in all gnomAD and ESP populations and not present in “COSMIC”
database at least two times or if the frequency of the variant is >10% in any
gnomAD and ESP populations. Variants with frequency >10% in any gnomAD or
ESP population were considered to be a common SNP irrespective of presence in
the COSMIC database.
Copy number analysis. To obtain raw copy-number estimates across the genome
of each sample, the number of unique templates mapping to each exome target
region (padded by 250 bp) was extracted from the BAM file. The raw estimates
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were normalized against coverage obtained from a panel of diploid normal samples.
A subset of targets was removed based on estimates of mean total copy-ratio and the
standard deviation of copy-ratio estimates within a panel of diploid normal samples.
The resulting total copy-ratio profiles were then segmented using an adaptation of
the circular binary segmentation algorithm, which includes information from all
patient samples when segmenting. Subsequently, the allele-specific copy number
was estimated by examining the template counts supporting alternative and refer-
ence alleles at germline heterozygous SNP sites within the 1000 Genomes Phase 3
variants. Of the 1000 Genomes Phase 3 variants, a patient was considered hetero-
zygous at a given locus based on the number of reference and alternative template
counts observed in all patient samples. The allele-specific template counts were then
used to infer allele-specific copy ratios as described previously serving as input into
ABSOLUTE v.1.4, which jointly estimated the fraction of cancer cells, cancer ploidy
and absolute allelic copy numbers across the genome31. For each somatic TP53
mutation, we estimated the fraction of cancer cells that harbors the mutation [its
CCF], represented as a distribution over the possible CCF values, between 0 and 1.
A CCF value of 1 indicates that mutations are present in 100% of clonal cells in the
sample. A CCF value of <1 indicates that the mutation is subclonal, and present in
only a subset of the clonal cells in the sample. Probability distributions over CCF
were computed for each TP53 mutation by correcting mutant and reference read
fractions for sample purity and local copy-number31,32.
Phasing. In each patient, a genotype was estimated at known polymorphic sites in
the 1000 Genomes project. Specifically, a subset of the polymorphic 1000 genomes
sites that intersected the whole exome targets. At each site, the evidence for a
genotype (AA, AB, BB) was calculated based on reference and alternate allele
counts and was additionally informed by population allele frequencies, which
served as priors for genotyping. Given the cohort of patients that were genotyped at
the polymorphic locations, haplotypes (AB vs. BA) were estimated using SHA-
PEIT2 and a haplotype panel from the 1000 Genome consortium. A hidden
markov model was used to integrate these estimates of haplotype along with
reference and alternate allele counts to create a maximum a posteriori estimate of
haplotype at each heterozygous SNP in each patient50.
Targeted deep sequencing. We selected 55 genes for targeted sequencing based
on their recurrent alteration in SDS exome cohort and myeloid malignancies13
(Supplementary Table 2). We included 48 single nucleotide polymorphisms (SNPs)
for establishing subject concordance of serial samples.
Library construction. An aliquot of genomic DNA (250 ng in 50 µL) was used as
the input into DNA fragmentation. Shearing was performed acoustically using a
Covaris focused-ultrasonicator, targeting 150 bp fragments. Library preparation
was performed using a commercially available kit provided by KAPA Biosystems
(KAPA HyperPrep Kit with Library Amplification product KK8504) and IDT’s
duplex UMI adapters. The libraries were then paired with unique 8-base dual index
sequences embedded within the p5 and p7 primers (purchased from IDT) added
during PCR. Enzymatic clean-ups were performed using Beckman Coulter
AMPure XP beads with elution volumes reduced to 30 µL to maximize library
concentration. In addition, during the post-enrichment SPRI cleanup, elution
volume was reduced to 30 µL to maximize library concentration, and a vortexing
step was added to maximize the amount of template eluted.
Post library construction quantification and normalization. Library quantifi-
cation was performed using the Invitrogen Quant-It broad range dsDNA quanti-
fication assay kit (Thermo Scientific Catalog: Q33130) with a 1:200 PicoGreen
dilution. Following quantification, each library is normalized to a concentration of
35 ng/µL, using Tris–HCl, 10 mM, pH 8.0.
In-solution hybrid selection. After library construction, hybridization and capture
are performed using the relevant components of IDT’s XGen hybridization and
wash kit and following the manufacturer’s suggested protocol, with several excep-
tions. A set of 12-plex pre-hybridization pools are created. These pre-hybridization
pools are created by equivolume pooling of the normalized libraries, Human Cot-1
and IDT XGen blocking oligos. The pre-hybridization pools undergo lyophilization
using the Biotage SPE-DRY. Post lyophilization, custom exome bait (TWIST
Biosciences) along with hybridization mastermix is added to the lyophilized pool
prior to resuspension. Samples are incubated overnight. Library normalization and
hybridization setup are performed on a Hamilton Starlet liquid handling platform,
while target capture is performed on the Agilent Bravo automated platform. Post
capture, a PCR is performed to amplify the capture material.
After post-capture enrichment, library pools are quantified using qPCR
(automated assay on the Agilent Bravo), using a kit purchased from KAPA
Biosystems with probes specific to the ends of the adapters. Based on qPCR
quantification, pools are normalized using a Hamilton Starlet to 2 nM and
sequenced using Illumina sequencing technology.
Cluster amplification and sequencing. Cluster amplification of library pools was
performed according to the manufacturer’s protocol (Illumina) using Exclusion
Amplification cluster chemistry and HiSeq X flowcells. Flowcells were sequenced
on v2 Sequencing-by-Synthesis chemistry for HiSeq X flowcells. The flowcells are
then analyzed using RTA v.2.7.3 or later. Each pool of whole genome libraries was
run on paired 151 bp runs, reading the dual-indexed sequences to identify mole-
cular indices and sequenced across the number of lanes needed to meet coverage
for all libraries in the pool.
Variant calling pipeline. Reads are aligned with bwa-mem 0.7.15. Duplex con-
sensus reads are called with fgbio 1.0 and realigned using bwa-mem. Consensus
reads are required to have reads from both families αβ and βα, and consensus reads
with Ns in excess of 5% of bases are discarded. Read one and two are soft-clipped
from the 5′ end by 10 bases to reduce errors due to end repair. Single nucleotide
and small insertion and deletion calling was performed with samtools-0.1.18
mpileup and Varscan 2.2.3. Variants were annotated to include information about
cDNA and amino acid changes, sequence depth, number, and percentage of reads
supporting the variant allele, population allele frequency in 1000 Genomes release
2.2.251, the Genome Aggregation Database (gnomAD)52, and presence in Catalog
of Somatic Mutations in Cancer (COSMIC), version 64.653. Variants were excluded
if they had fewer than three total duplex-reassembled alternate reads at the position
or had variant allele fraction <0.1%, fell outside of the target coordinates, had
excessive read strand bias, had excessive number of calls in the local region, caused
synonymous changes, or were recurrent small insertions/deletions at low variant
allele fraction adjacent to homopolymer repeat regions. Somatic status was
determined using cultured fibroblast DNA as a germline reference tissue com-
parator. Individual single nucleotide substitutions and small insertions or deletions
were evaluated as candidate drivers of MDS or bone marrow failure based on gene-
specific characteristics, then curated manually and classified as MDS driver
mutations or pathogenic bone marrow failure mutations based on genetic criteria
and literature review13,54,55. Variant level details are available in Supplementary
Table 6. All interpretation of variants was blinded to clinical characteristics and
thus agnostic to variables including age, sex, diagnosis, treatment status, and
clinical outcomes; the genetic analysis was completed and locked prior to merging
with any clinical data.
EIF6 model and mutational analysis. A human EIF6 structural model was gen-
erated using Rosetta56,57, and the structure was then further refined in Rosetta
using the FastRelax algorithm58 with the Rosetta-ICO energy function59. Individual
point mutations were evaluated for the predicted change in protein stability
(ΔΔGmutation) by introducing point mutations into the EIF6 structural model and
calculating the change in energy (i.e. Rosetta total_score) relative to the native
structure. The residues at the interface between EIF6 and RPL23 are 100% con-
served between our model of human EIF6 and D. discoideum EIF6; thus,
PDB ID 5ANB22 was refined in the same way and used for the ΔΔGbind
calculations, which were performed using the Flex ddG method23. All scripts
that were used for refinement and analysis are provided as Supplementary Soft-
ware 1. Conservation scores were calculated using the ConSurf server60, and
structural images were generated using PyMOL Molecular Graphics System
version 1.8.4.0.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
The whole exome, single cell, and targeted sequencing data are deposited in the European
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